This Article Full Text Full Text (PDF) All Versions of this Article: 50/4/596    most recent HYPERTENSIONAHA.106.076216v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chappell, M. C. Search for Related Content PubMed PubMed Citation Articles by Chappell, M. C. Pubmed/NCBI databases Substance via MeSH Related Collections Remodeling ACE/Angiotension receptors Animal models of human disease Hypertrophy Type 1 diabetes

(Hypertension. 2007;50:596.)
© 2007 American Heart Association, Inc.

Hypertension Highlights

Emerging Evidence for a Functional Angiotensin-Converting Enzyme 2-Angiotensin-(1-7)-Mas Receptor Axis

More Than Regulation of Blood Pressure?

From the Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC.

Correspondence to Mark C. Chappell, Hypertension and Vascular Disease Center, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27015. E-mail mchappel@wfubmc.edu

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
From the initial description of renin activity over a century ago, the ongoing study of the renin-angiotensin (Ang)-aldosterone system (RAAS) continues to yield unexpected findings that redefine the functional nature of this system, as well as our concepts on the mechanisms of cardiovascular regulation. The functional arc of the RAAS can no longer be viewed solely in terms of increasing blood pressure and inducing vasoconstriction, although these still remain the dominant aspects of at least the angiotensin II receptor subtype 1 (AT₁R) pathway. There is clearly compelling evidence that other components of the RAAS may buffer actions, because the Ang II-AT₂ receptor pathway uses the identical ligand coupled to a different receptor subtype to evoke, in many cases, actions that oppose AT₁ activation¹ (for a more extensive review). Moreover, parallel pathways within the RAAS result in novel products distinct from Ang II that require additional "Ang"-converting enzymes (ACEs) and unique receptors for these products. Indeed, the recent discoveries of ACE2, the Ang-(1-7) [AT_(1-7)] receptor, and Ang-(1-12)² as a potentially new precursor add significant impetus to revise the RAAS as multiple systems that may amplify or oppose one another (see the Figure). In this brief review, the current evidence for the physiological relevance of these new components of the RAAS is assessed.

View larger version (57K):   Figure. Cascade of the processing of angiotensin peptides and their interaction with AT1 and AT(1-7) receptor systems. ACE cleaves Ang I, releasing the dipeptide His-Leu to form Ang II, and ACE2 subsequently hydrolyzes Ang II to . . . [Full Text of this Article]

This article has been cited by other articles:

				J. A. Jessup, B. M. Westwood, M. C. Chappell, and L. Groban Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat Therapeutic Advances in Cardiovascular Disease, August 1, 2009; 3(4): 245 - 257. [Abstract] [PDF]

				S. H. Lindsey, J. A. Cohen, K. B. Brosnihan, P. E. Gallagher, and M. C. Chappell Chronic Treatment with the G Protein-Coupled Receptor 30 Agonist G-1 Decreases Blood Pressure in Ovariectomized mRen2.Lewis Rats Endocrinology, August 1, 2009; 150(8): 3753 - 3758. [Abstract] [Full Text] [PDF]

				J. M. Stewart, A. J. Ocon, D. Clarke, I. Taneja, and M. S. Medow Defects in Cutaneous Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7) Production in Postural Tachycardia Syndrome Hypertension, May 1, 2009; 53(5): 767 - 774. [Abstract] [Full Text] [PDF]

				L. Tang, L. C. Carey, J. Bi, N. Valego, X. Sun, P. Deibel, J. Perrott, J. P. Figueroa, M. C. Chappell, and J. C. Rose Gender differences in the effects of antenatal betamethasone exposure on renal function in adult sheep Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R309 - R317. [Abstract] [Full Text] [PDF]

				H. A. Shaltout, J. P. Figueroa, J. C. Rose, D. I. Diz, and M. C. Chappell Alterations in Circulatory and Renal Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 in Fetal Programmed Hypertension Hypertension, February 1, 2009; 53(2): 404 - 408. [Abstract] [Full Text] [PDF]

				K. D. Pendergrass, N. T. Pirro, B. M. Westwood, C. M. Ferrario, K. B. Brosnihan, and M. C. Chappell Sex differences in circulating and renal angiotensins of hypertensive mRen(2).Lewis but not normotensive Lewis rats Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H10 - H20. [Abstract] [Full Text] [PDF]

				J. F. Giani, M. M. Gironacci, M. C. Munoz, D. Turyn, and F. P. Dominici Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity Exp Physiol, May 1, 2008; 93(5): 570 - 578. [Abstract] [Full Text] [PDF]

				H. Ji, S. Menini, W. Zheng, C. Pesce, X. Wu, and K. Sandberg Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17{beta}-oestradiol regulation of renal pathology in renal wrap hypertension in rats Exp Physiol, May 1, 2008; 93(5): 648 - 657. [Abstract] [Full Text] [PDF]

				R. A. S. Santos, A. J. Ferreira, and A. C. Simoes e Silva Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis Exp Physiol, May 1, 2008; 93(5): 519 - 527. [Abstract] [Full Text] [PDF]

				P. J. Garabelli, J. G. Modrall, J. M. Penninger, C. M. Ferrario, and M. C. Chappell Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart Exp Physiol, May 1, 2008; 93(5): 613 - 621. [Abstract] [Full Text] [PDF]

				D. I. Diz, M. A. Garcia-Espinosa, S. Gegick, E. N. Tommasi, C. M. Ferrario, E. Ann Tallant, M. C. Chappell, and P. E. Gallagher Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats Exp Physiol, May 1, 2008; 93(5): 694 - 700. [Abstract] [Full Text] [PDF]

				A. J. Trask, J. A. Jessup, M. C. Chappell, and C. M. Ferrario Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2242 - H2247. [Abstract] [Full Text] [PDF]

				J. M. C. Connell, S. M. MacKenzie, E. M. Freel, R. Fraser, and E. Davies A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function Endocr. Rev., April 1, 2008; 29(2): 133 - 154. [Abstract] [Full Text] [PDF]